<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813059</url>
  </required_header>
  <id_info>
    <org_study_id>edmargolin</org_study_id>
    <nct_id>NCT00813059</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy</brief_title>
  <official_title>Intravitreal Bevacizumab for Treatment of the Second Eye With Non-Arteritic Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic&#xD;
      nerve (the &quot;cable&quot; going from the eye to the brain) resulting in decreased vision. About 15%&#xD;
      of patients will experience NAION in the second eye; many of these patients will be left&#xD;
      legally blind.&#xD;
&#xD;
      Currently, there is no treatment for NAION and for patients in whom the second eye becomes&#xD;
      involved by the disease the outcome can be devastating.&#xD;
&#xD;
      The investigators are conducting a study where the investigators will inject a medication&#xD;
      into the involved eye of patients with NAION. This medication might decrease the swelling of&#xD;
      the optic nerve and improve their vision in that eye.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NAION produces an ischemic insult in the optic nerve head presumably due to the hypoperfusion&#xD;
      of the short ciliary arteries that supply it. This leads to the release of vascular&#xD;
      endothelial growth factor (VEGF) and swelling of the affected area of the nerve. Vascular&#xD;
      endothelial growth factor (VEGF) causes a rapid and reversible increase in vascular&#xD;
      permeability and thus vasogenic edema of the affected area of the optic nerve head.&#xD;
      Subsequently, increased pressure from the swelling of the affected segment causes compression&#xD;
      and infarction of the previously not affected parts of the optic nerve by creating a sort-of&#xD;
      &quot;compartment syndrome&quot;.&#xD;
&#xD;
      Bevacizumab is a known anti-Vascular Endothelial Growth Factor (VEGF) agent. It is the&#xD;
      investigators hypothesis that by injecting bevacizumab intra-vitreally the vasogenic edema&#xD;
      will be reduced, preserving viable but threatened optic nerve tissue. One recent case report&#xD;
      described a patient with sequential NAION treated with intra-vitreal bevacizumab who&#xD;
      demonstrated significant improvement in visual acuity and on visual field testing (1). An&#xD;
      editorial in the same issue of the Journal of Neuro-Ophthalmology in which this article&#xD;
      appeared suggested that if the small studies evaluating intra-vitreal injections of&#xD;
      bevacizumab in NAION would support its use in this disease, a large multi-center trial could&#xD;
      be planned (2).&#xD;
&#xD;
      Intra-vitreal injections of bevacizumab have proven to be very safe in treatment of&#xD;
      age-related macular degeneration (3). Because the patients that the investigators are&#xD;
      planning to enroll in this study are faced with the real possibility of blindness with no&#xD;
      therapeutic modality currently available to improve their visual outcome, the investigators&#xD;
      believe that offering them intra-vitreal bevacizumab injection that might halt the&#xD;
      progression of the visual acuity and visual field loss if our hypothesis is correct, would&#xD;
      greatly improve their chances of avoiding blindness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who gained three or more lines of vision at six months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non-arteritic Anterior Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)</intervention_name>
    <description>Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly diagnosed NAION (within the past 30 days but preferably within the&#xD;
             first 14).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to give informed consent&#xD;
&#xD;
          -  Patient with:&#xD;
&#xD;
               -  uncontrolled glaucoma&#xD;
&#xD;
               -  pregnancy&#xD;
&#xD;
               -  lactation&#xD;
&#xD;
               -  proliferative diabetic retinopathy&#xD;
&#xD;
               -  active clinically significant diabetic macular edema&#xD;
&#xD;
               -  active uveitis&#xD;
&#xD;
               -  prior treatment with intraocular steroids that incited significant increase in&#xD;
                  intra-ocular pressure&#xD;
&#xD;
               -  other known causes of decreased visual acuity in the recently involved eye such&#xD;
                  as significant dry or wet macular degeneration&#xD;
&#xD;
               -  previous history of other optic neuropathies&#xD;
&#xD;
               -  previous history of ocular trauma that resulted in decreased visual acuity&#xD;
&#xD;
          -  Patients with baseline amblyopia in the newly involved eye and visual acuity worse&#xD;
             than 20/50 prior to the onset of NAION&#xD;
&#xD;
          -  Previous treatment for any ocular condition with any investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Margolin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward Margolin, MD</last_name>
    <phone>416-586-4800</phone>
    <phone_ext>5137</phone_ext>
    <email>mjiharev@mtsinai.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Hospital, University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Margolin, MD</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>5137</phone_ext>
      <email>mjiharev@mtsinai.on.ca</email>
    </contact>
    <investigator>
      <last_name>Edward Margolin, MD, FRSCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Bennett JL, Thomas S, Olson JL, Mandava N. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol. 2007 Sep;27(3):238-40.</citation>
    <PMID>17895825</PMID>
  </reference>
  <reference>
    <citation>Kelman SE. Intravitreal triamcinolone or bevacizumab for nonarteritic anterior ischemic optic neuropathy: do they merit further study? J Neuroophthalmol. 2007 Sep;27(3):161-3.</citation>
    <PMID>17895813</PMID>
  </reference>
  <reference>
    <citation>Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006 Nov;90(11):1344-9. Epub 2006 Jul 19.</citation>
    <PMID>16854824</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai Hospital, Canada</investigator_affiliation>
    <investigator_full_name>Edward Margolin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>NAION</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

